NCT06510868 Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
| NCT ID | NCT06510868 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Myelodysplastic Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 45 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2028-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 45 participants in total. It began in 2024-08-01 with a primary completion date of 2028-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective observational study which aims to identify individuals predisposed to developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) could improve patient outcomes in different ways. First, it will enable improved patient selection for PRRT where alternative treatment options are available. Second, understanding the final pathway and how it is modulated by PRRT could allow the design of strategies to halt this process. Third, while it is unknown whether the development of MDS and AML is a late effect of radiopharmaceuticals in general or it is confined to cancer populations or specific radioisotopes will need to be confirmed. Finally, understanding this devastating complication is expected to be the cornerstone towards advancing radiopharmaceuticals' role in the adjuvant setting.
Eligibility Criteria
Inclusion Criteria: * ECOG 0-3 * Life expectancy \> 6 months * Informed consent and willingness to undergoing serial genetic panel CHIP testing. * Cohort Specific criteria 1. Cohort A: PRRT completed within 5 years of enrolment 2. Cohort B: PRRT planned to commence within 4 months of enrolment 3. Cohort C: diagnosis of MDS or AML following prior PRRT. Exclusion Criteria: * Unwillingness to provide blood sample and follow up as per protocol
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06510868 clinical trial?
This trial is open to participants of all sexes, studying Myelodysplastic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06510868 currently recruiting?
Yes, NCT06510868 is actively recruiting participants. Contact the research team at rebecca.wong@uhn.ca for enrollment information.
Where is the NCT06510868 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06510868 clinical trial?
NCT06510868 is sponsored by University Health Network, Toronto. The trial plans to enroll 45 participants.